Nearly three years after its introduction, the CMS’s Oncology Care Model (OCM) remains the most ambitious and far-reaching initiative to shift cancer care toward value-based models.
Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute whose research is focused on apoptosis and functional diagnostics, has been tapped by the Trump administration to become the 18th director of the National Cancer Institute.
